Biovail Names John Sebben Vice-President Global Manufacturing.

TORONTO -- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that it has hired pharmaceutical industry veteran John Sebben to become its new Vice-President, Global Manufacturing. Mr. Sebben, who will be based at the company's head office in Mississauga, ON, will officially join the company August 4, 2004, replacing Praveen Tyle, who has left Biovail to pursue other interests.

"The addition of John Sebben to Biovail's senior management team is reflective of the company's commitment to continually add depth and strength to its management team," said Eugene Melnyk, Chairman and Chief Executive Officer. "John brings a solid track record of success in manufacturing operations which is of critical importance as demand for Biovail's products, most notably CARDIZEM(R) LA and WELLBUTRIN(R) XL, continues to increase and in anticipation of the commercialization of high-volume pharmaceutical products, such as Ralivia(TM) ER in the United States and TIAZAC(R) XC in Canada."

Most recently, Mr. Sebben was Vice-President, Operations, at TorPharm, a Toronto-based division of Apotex Inc., the largest generic pharmaceutical manufacturer in Canada. During his tenure, he oversaw the company's operational processes, including manufacturing, packaging, planning, logistics, warehousing, purchasing, and production maintenance.

Before joining TorPharm in January 2002, Mr. Sebben spent more than 13 years at GlaxoSmithKline in Mississauga, where he held a series of progressively responsible senior positions, including Director, Operations and Director, Supply Chain. From 1986-1989, Mr. Sebben served as Director, Materials Management, for Sandoz Canada in Whitby, ON. Previously, he spent five years with Travenol Canada, where he held a number of materials-management and business-planning roles.

Mr. Sebben holds a Master of Business Administration degree from York University in Toronto, and a Bachelor of Science degree from the University of Toronto. He resides with his family in Oakville, ON, just west of Toronto.

About Biovail Corporation

Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug-delivery technologies. For more information about Biovail, visit the company's website at www.biovail.com.

For further information, please contact Ken Howling at 905-286-3000 or send inquiries to [e-mail].

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995.

To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.